Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Infection
; 51(5): 1577-1581, 2023 Oct.
Article
en En
| MEDLINE
| ID: mdl-37076752
ABSTRACT
PURPOSE:
People with hematologic malignancies have a significantly higher risk of developing severe and protracted forms of SARS-CoV-2 infection compared to immunocompetent patients, regardless of vaccination status.RESULTS:
We describe two cases of prolonged SARS-CoV-2 infection with multiple relapses of COVID-19 pneumonia in patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. The aim is to highlight the complexity of SARS-CoV-2 infection in this fragile group of patients and the necessity of evidence-based strategies to treat them properly.CONCLUSIONS:
Patients with hematological malignancies treated with bendamustine and anti-CD20 antibodies had a significant risk of prolonged and relapsing course of COVID-19. Specific preventive and therapeutic strategies should be developed for this group of patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Linfoma Folicular
/
Neoplasias Hematológicas
/
COVID-19
Límite:
Humans
Idioma:
En
Revista:
Infection
Año:
2023
Tipo del documento:
Article
País de afiliación:
Italia